scholarly journals Hepatitis B Surface Antigen Positivity Is an Independent Unfavorable Prognostic Factor in Diffuse Large B‐Cell Lymphoma in the Rituximab Era

2020 ◽  
Vol 25 (9) ◽  
pp. 793-802 ◽  
Author(s):  
Chieh‐Lung Cheng ◽  
Sheng‐Chuan Huang ◽  
Jia‐Hong Chen ◽  
Chao‐Hung Wei ◽  
Wei‐Quan Fang ◽  
...  
Keyword(s):  
Prognostic Factor ◽  
Hepatitis B ◽  
B Cell ◽  
Surface Antigen ◽  
Cell Lymphoma ◽  
Hepatitis B Surface Antigen ◽  
B Cell Lymphoma ◽  
Large B Cell Lymphoma ◽  
Independent Unfavorable Prognostic Factor ◽  
Large B Cell

Fulminant B hepatitis in a surface antigen and hepatitis B DNA-negative patient with diffuse large B-cell lymphoma after CHOP chemotherapy plus rituximab

2007 ◽  
Vol 48 (2) ◽  
pp. 431-433 ◽  
Author(s):  
Michiko Yamagata ◽  
Toshimitsu Murohisa ◽  
Kohei Tsuchida ◽  
Yutaka Okamoto ◽  
Saburo Tsunoda ◽  
...  
Keyword(s):  
Hepatitis B ◽  
B Cell ◽  
Surface Antigen ◽  
Cell Lymphoma ◽  
B Cell Lymphoma ◽  
Chop Chemotherapy ◽  
Negative Patient ◽  
Large B Cell Lymphoma ◽  
Large B Cell

Prospective Analysis of Hepatitis B Virus Reactivation in Patients With Diffuse Large B-Cell Lymphoma After Rituximab Combination Chemotherapy

2010 ◽  
Vol 28 (34) ◽  
pp. 5097-5100 ◽  
Author(s):  
Nozomi Niitsu ◽  
Yuki Hagiwara ◽  
Ken Tanae ◽  
Mika Kohri ◽  
Naoki Takahashi
Keyword(s):  
Hepatitis B ◽  
B Cell ◽  
Cell Lymphoma ◽  
Hepatitis B Surface Antigen ◽  
B Cell Lymphoma ◽  
Hbv Dna ◽  
Hbv Reactivation ◽  
Large B Cell Lymphoma ◽  
B Virus ◽  
Large B Cell

Purpose Recently, there have been reports of hepatitis B virus (HBV) reactivation after rituximab combination chemotherapy in hepatitis B surface antigen (HBsAg) –negative patients with B-cell lymphoma. In this prospective study, the frequency of and risk factors for HBV reactivation in patients who were receiving rituximab chemotherapy were examined. Patients and Methods A total of 314 HBsAg-negative patients with diffuse large B-cell lymphoma were treated with rituximab chemotherapy. Antibody to hepatitis B surface antigen (anti-HBs) and antibody to hepatitis B core antigen (anti-HBc) tests were performed in all patients. In patients who were positive for anti-HBs and/or anti-HBc, serum HBV-DNA was measured. Results Of the 314 patients, 51 (16.2%) were HBV carriers. HBV reactivation occurred during or after rituximab chemotherapy in six patients (12%). All six patients who developed HBV reactivation were anti-HBc positive, and three of them were also anti-HBs positive. In these six patients, the pretreatment anti-HBs titer was low. Entecavir administration was started when serum HBV DNA became positive, and serum HBV-DNA became negative within 1 to 3 weeks. Rituximab chemotherapy was then continued. Risk factors for HBV reactivation were being male and having a low anti-HBs titer. Conclusion HBV reactivation occurred in some patients who had been anti-HBs negative or had a low anti-HBs level. In addition, HBV reactivation occurred at an early stage of rituximab chemotherapy, but rituximab chemotherapy could be continued after entecavir administration reduced the serum HBV-DNA level. Entecavir (BMS 200495) prophylaxis was not performed when rituximab chemotherapy was started, and it was thought that entecavir could be started when serum HBV-DNA increased.

Geriatric nutritional risk index as a prognostic factor in patients with diffuse large B cell lymphoma

2018 ◽  
Vol 97 (6) ◽  
pp. 999-1007 ◽  
Author(s):  
Yusuke Kanemasa ◽  
Tatsu Shimoyama ◽  
Yuki Sasaki ◽  
Tsunekazu Hishima ◽  
Yasushi Omuro
Keyword(s):  
Prognostic Factor ◽  
B Cell ◽  
Cell Lymphoma ◽  
Risk Index ◽  
B Cell Lymphoma ◽  
Nutritional Risk ◽  
Geriatric Nutritional Risk Index ◽  
Large B Cell Lymphoma ◽  
Nutritional Risk Index ◽  
Large B Cell

scholarly journals Consecutive Hypoalbuminemia Predicts Inferior Outcome in Patients With Diffuse Large B-Cell Lymphoma

2021 ◽  
Vol 10 ◽  
Author(s):  
Xiaolei Wei ◽  
Jingxia Zheng ◽  
Zewen Zhang ◽  
Qiongzhi Liu ◽  
Minglang Zhan ◽  
...  
Keyword(s):  
Prognostic Factor ◽  
Serum Albumin ◽  
B Cell ◽  
Validation Cohort ◽  
Cell Lymphoma ◽  
B Cell Lymphoma ◽  
Training Cohort ◽  
Large B Cell Lymphoma ◽  
Large B Cell ◽  
Low Serum

The prognostic value of albumin changes between diagnosis and end-of-treatment (EoT) in diffuse large B-cell lymphoma (DLBCL) remains unknown. We retrospectively analyzed 574 de novo DLBCL patients treated with R-CHOP from our and two other centers. All patients were divided into a training cohort (n = 278) and validation cohort (n = 296) depending on the source of the patients. Overall survival (OS) and progression-free survival (PFS) were analyzed by the method of Kaplan–Meier and Cox proportional hazard regression model. In the training cohort, 163 (58.6%) patients had low serum albumin at diagnosis, and 80 of them were present with consecutive hypoalbuminemia at EoT. Patients with consecutive hypoalbuminemia showed inferior OS and PFS (p = 0.010 and p = 0.079, respectively). Similar survival differences were also observed in the independent validation cohort (p = 0.006 and p = 0.030, respectively). Multivariable analysis revealed that consecutive hypoalbuminemia was an independent prognostic factor OS [relative risk (RR), 2.249; 95% confidence interval (CI), 1.441–3.509, p < 0.001] and PFS (RR, 2.001; 95% CI, 1.443–2.773, p < 0.001) in all DLBCL patients independent of IPI. In conclusion, consecutive hypoalbuminemia is a simple and effective adverse prognostic factor in patients with DLBCL, which reminds us to pay more attention to patients with low serum albumin at EoT during follow-up.

Sign in / Sign up

Export Citation Format

Share Document